$NEO: The Cancer Lab That Just Turned Profitable

On July 28, 2026, NeoGenomics reported its first quarterly net profit: $2.24 million. That is not a large number. For a company that burned through years of losses and carried the reputation of a perpetual turnaround, it is a significant one.

Then, on August 26, the company announced that its RaDaR ST molecular residual disease assay had received Medicare coverage for immunotherapy treatment response monitoring in solid tumors. That was the third MolDX indication for RaDaR ST. Two more are pending approval by year end. Management had not spoken publicly about either development before the Morgan Stanley 24th Annual Global Healthcare Conference, scheduled for September 15.

We think the market is treating $NEO as a story that has mostly played out. The stock is up roughly 170% over the past 52 weeks. But the margin inflection is accelerating, not plateauing, and the MRD coverage expansion is only now reaching critical mass in a channel that takes years to build. The thesis here is that the street has repriced the turnaround but not yet the compounding.

The 60 second version

• NeoGenomics is the only pure play scaled oncology reference laboratory in the United States, serving oncologists, pathologists, and hospital systems with cancer specific clinical testing and companion diagnostics.
• The shift: next generation sequencing and molecular residual disease testing are moving from academic centers into community oncology, and NeoGenomics is the best positioned independent laboratory to capture that volume.
• The number: operating margin went from negative 26.3% to negative 4.8% year over year in Q2 2026, with NGS revenue growing 26% in the same period. First quarterly net profit in the company’s history as a pure play oncology lab.
• The catalyst: Morgan Stanley 24th Annual Global Healthcare Conference fireside chat on September 15, 2026, the first public management appearance since the August 26 Medicare coverage win for RaDaR ST immunotherapy monitoring.
• The main risk: RaDaR ST and PanTracer growth depend on continued favorable MolDX coverage decisions. A denial on either of the two pending submissions would slow volume and compress the margin path the market is beginning to price.
• Market capitalisation approximately $2.2 billion as of September 3, 2026.

The detail that should stop you is the attachment rate. When a physician orders a RaDaR ST MRD test, roughly 30% of those orders come with a concurrent test from elsewhere in the NeoGenomics portfolio. That is not a feature they advertise loudly. It is buried in the investor slides. What it means is that each new MRD indication does not just add its own revenue line. It pulls through existing volume across cytogenetics, flow cytometry, and molecular panels that would otherwise have gone to a competing lab.

Our thesis is this: the market has repriced the turnaround but not the compounding. NeoGenomics is now generating positive free cash flow, holds $145.5 million in cash after a June 2026 refinancing that pushed its major debt maturity to 2032, and is expanding into the fastest growing corner of oncology diagnostics with a channel that competitors cannot replicate quickly. The September 15 conference is the first time management speaks since the third MRD indication. That gap between news and explanation is where the mispricing sits.

The shift

Oncology testing spent most of the last decade concentrated at large academic medical centers. The tools required for next generation sequencing were expensive, the reimbursement landscape was fragmented, and community oncologists, who treat the majority of cancer patients in the United States, mostly sent samples to whoever made ordering easiest. That was usually a general diagnostics lab with an oncology panel attached, not a specialist.

Two things changed. First, the clinical evidence base for MRD testing matured fast enough that major payers, including Medicare through the MolDX program, began issuing formal coverage determinations for specific indications. Coverage converts an experimental add on into a billable, repeatable test. Second, FDA companion diagnostic approvals created a new category of test that is not optional: if you prescribe certain therapies, you need a specific assay first. NeoGenomics holds one of those approvals right now, the PTEN IHC CDx for prostate cancer, and is building toward more.

The result is that the economics of community oncology testing are shifting toward specialists. General labs are not well positioned to invest in the laboratory development, FDA submission work, and payer negotiation that MRD and companion diagnostics require. NeoGenomics is. It has been doing that work for years and is now harvesting the coverage wins at the moment when community oncologist volume is large enough to matter.

We are somewhere in the middle of this curve. MolDX coverage for solid tumor MRD is real but incomplete. Private payer adoption lags Medicare by one to three years in this category. The volume is growing but has not yet reached the inflection that a full private payer coverage cycle would trigger. That lag is the gap between where the business is and where the market will eventually have to price it.

The company

NeoGenomics operates a national network of CAP accredited, CLIA certified laboratories that do nothing but cancer testing. No routine bloodwork, no wellness panels, no general reference testing. Everything in the building is oncology: cytogenetics, flow cytometry, molecular genetic testing, NGS, and now MRD assays. That focus is not incidental. It shapes the culture, the sales force, and the laboratory economics in ways that matter when a community oncologist is deciding where to send a complex biopsy.

The company has been around for decades but spent years losing money on a growth at any cost strategy that produced revenue without margin. The current management team, led by CEO Chris Smith, who joined in 2022, has spent three years restructuring the cost base, pruning the pharma services segment where it did not make economic sense, and investing heavily in the NGS and MRD product lines that carry structurally higher average unit prices. That work showed up in the numbers for the first time at scale in Q2 2026.

The detail that only shows up in the filings: the June 2026 convertible note refinancing retired $276 million of the 2028 notes, issued $305.7 million in new 0.75% notes due 2032, and simultaneously repurchased $25 million of common stock, all wrapped in capped call transactions to limit dilution from conversion. That is not a company managing a liquidity crisis. That is a management team with enough confidence in the forward cash generation to buy back stock at the same time they refinance debt. The capped call structure also means that the dilution overhang most investors assume comes with convertibles is significantly reduced at current prices.

The numbers and what the street expects

Revenue in Q2 2026 came in at $201.7 million, up 11.2% year over year. That was the fifth consecutive quarter of approximately 10 to 11% top line growth. Clinical revenue, which is about 95% of the business, grew 14% with average unit price up 12%. NGS revenue specifically grew 26% and now accounts for more than one third of clinical volume. The pharma segment fell 26% and remains a drag, though at 5% of total revenue its effect on the consolidated number is limited.

Operating margin moved from negative 26.3% to negative 4.8% in the same period year over year. That is a 21-point improvement in twelve months. Management guided full year 2026 adjusted EBITDA to $56 to $58 million, with the midpoint of $57 million sitting above the prior analyst consensus of $56.18 million. Full year revenue is guided to $802 to $806 million, raised twice during 2026. Adjusted EPS guidance for the full year is $0.19 at the midpoint, ahead of prior consensus by roughly 2.8%.

Twelve analysts cover the name per S&P Global. The consensus is Buy, eight Buy to four Hold, zero Sell. The median 12-month price target is $19, with a range of $16 on the low end to $35 on the high end. Craig Hallum raised its target to $19 from $17 following Q2. Needham moved to $19 from $15. Revisions have been uniformly upward over the past 90 days. The gap between the $16 floor and the $35 ceiling suggests the analyst community is not yet aligned on how far the margin expansion can go.

Q3 2026 consensus EPS is approximately $0.05 per TradingView, with revenue in the $205 to $207 million range implied by the full year run rate. We could not confirm the Q3 revenue figure from a single aggregated consensus database and flag it accordingly. If management is right that RaDaR ST volume is accelerating and the September immunotherapy indication adds ordering momentum, Q3 has a plausible path to the high end of that implied range.

Cash at June 30 was $145.5 million. Q2 operating cash flow was approximately $20 million, positive for the first time, and free cash flow margin reached 12.4%, up from 7.7% in the prior year period. Net long term debt is $374.2 million, with the majority now due in 2032. There is no near term maturity cliff. The DOJ and OIG HHS consulting services matter was settled in July 2026 for $9.8 million, below the $11.2 million reserve the company had set aside, which freed a small amount of capital and removed what had been a persistent compliance overhang.

One number that does not fit the bullish story cleanly: the pharma segment. It represents 5% of revenue and fell 26% year over year in Q2. Management calls it “opportunistic” and expects recovery by 2027. We find that framing vague. Pharma services revenue can be lumpy because it depends on contract by contract arrangements with drug developers, and the timing of when those contracts close is genuinely hard to predict. But 26% is a steep decline and the recovery timeline is not specific. We are watching it without overweighting it, given its size relative to the whole.

Why it wins

NeoGenomics wins in community oncology because no one else has built what it has built there. Quest and LabCorp are general reference laboratories with oncology panels. They serve thousands of specialties and have no particular reason to invest in the regulatory infrastructure, laboratory development, and sales relationship depth that winning in community oncology cancer testing requires. Academic medical centers do advanced testing but do not compete for community referrals aggressively. The independent oncology reference laboratory category has effectively one scaled player: NeoGenomics.

The moat inside the moat is the Epic Aura EHR integration. A community oncologist whose practice runs on Epic can order a NeoGenomics test without leaving the patient record. That is a friction advantage that compounds over time. Once a practice is integrated and the ordering workflow is established, switching requires IT work, retraining, and a reason to bother. Competitors cannot replicate the integration overnight even if they want to.

Natera, the closest competitor in MRD testing, voluntarily withdrew its RaDaR patent appeal in late 2025. That removed what had been the primary IP risk to NeoGenomics’s MRD program. The competitive landscape for MRD in solid tumors now favors the lab with the broadest coverage footprint and the deepest community oncologist relationships, which is NeoGenomics. The 30% concurrent test attachment rate is the financial expression of that depth. Ordering one test turns into ordering two.

What could go wrong

The entire margin expansion thesis depends on continued favorable coverage decisions from MolDX, the regional Medicare coverage program that governs advanced molecular diagnostics. Two RaDaR ST submissions are pending by year end, with a third expected in the first half of 2027. A denial on either pending submission would not destroy the business, but it would slow the volume ramp materially and compress the AUP growth that is driving the margin improvement. MolDX decisions are not predictable on a timeline and can take longer than management anticipates.

Private payer coverage is the larger long term risk. Medicare MolDX coverage is necessary but not sufficient. The major commercial insurers, which represent a larger share of the oncology patient population by dollar value, have their own coverage determination processes, and they lag Medicare by one to three years in this category. If private payer adoption of RaDaR ST moves slowly, the total addressable volume is smaller for longer than the current growth trajectory implies.

The stock has already run 170% in a year. Short interest sits at roughly 12% of float, which means there is a meaningful short base still in place, and any negative surprise on coverage or volume could trigger a sharp reversal in a stock that is no longer cheap on near term multiples. The bear case is not that NeoGenomics fails. The bear case is that the coverage expansion takes two years instead of one, the pharma segment stays depressed, and the stock that the market has already repriced from turnaround to growth story finds itself priced for growth that arrives later than expected.

The investment thesis

The market has repriced the turnaround but not the compounding; the specific gap is in RaDaR ST coverage expansion, which the street is modeling conservatively at a moment when the actual MolDX coverage wins are arriving ahead of that model.

What has to be true for this to work: MolDX approves at least one of the two pending RaDaR ST indications by year end 2026, private payer coverage for at least one indication begins to move in 2027, and the community oncology sales expansion to 160 or more commercial reps sustains the volume growth that is driving AUP higher. None of those things require NeoGenomics to do something it has not already demonstrated it can do. The wins are in process. The reps are being hired. The question is timing.

What the market appears to believe instead is that the margin expansion has been substantially priced in at current levels, and that further upside requires a catalyst the street cannot yet see. We disagree on the timing of the RaDaR ST coverage cycle. Three indications in and with two pending, this program is entering the phase where clinical adoption compounds. The September 15 conference is the first time management addresses the third indication publicly. That is a specific, dated opportunity for the gap between the news and the market’s understanding of it to close.

The pharma segment is currently valued by no one. At 5% of revenue and declining, the street has effectively assigned it zero weight in forward models. If it recovers toward its prior run rate by 2027, it adds incremental revenue against a fixed cost base, which means it lands as margin, not just revenue. That optionality is not in the consensus.

This is a name to hold through a catalyst sequence that runs from September 15 through the Q3 earnings print around November 10. The thesis plays out over 12 to 18 months as MolDX coverage expands and private payer adoption begins to move. The falsification is simple: if MolDX denies both pending RaDaR ST submissions by year end 2026, the volume ramp the margin thesis depends on is delayed by at least a year, and the current valuation is hard to defend.

What we are watching

• September 15, 2026: Morgan Stanley 24th Annual Global Healthcare Conference fireside chat. First management comments on the August 26 RaDaR ST immunotherapy Medicare coverage win and any updated volume or pipeline commentary.
• On or before December 31, 2026: MolDX coverage decision on the first of two pending RaDaR ST indications, as guided by management on the Q2 call.
• On or before December 31, 2026: MolDX coverage decision on the second pending RaDaR ST indication.
• Around November 10, 2026: Q3 2026 earnings release. Key metrics to track: NGS revenue growth rate, RaDaR ST volume commentary, AUP trend, pharma segment trajectory, and whether full year FCF guidance is reiterated or raised.
• Q4 2026 or Q1 2027: Any private payer coverage determination for RaDaR ST from a major commercial insurer, which would signal the beginning of the broader adoption cycle.
• H1 2027: Third RaDaR ST MolDX submission expected; timing of filing and any MolDX response would extend or compress the coverage ramp timeline.

The bottom line

NeoGenomics is a pure play oncology laboratory at the exact moment when oncology laboratory economics are improving structurally. NGS and MRD testing carry higher average unit prices than the legacy panel business. The community oncology channel, where most cancer patients are actually treated, is only beginning to adopt MRD in a reimbursed, repeatable way. NeoGenomics built the laboratory infrastructure, earned the FDA approvals, won the MolDX coverage decisions, and has the only national independent oncology sales force with the relationships to convert that coverage into volume. The first quarterly profit arrived in Q2 2026. The coverage expansion is arriving in real time.

The stock has run hard and is not cheap. Anyone coming to this story now is not buying the turnaround at the bottom. What is left to buy, if the thesis is right, is the compounding phase of a specialty platform that the street is still treating as a recovery story. The Morgan Stanley conference on September 15 and the Q3 print in November are the near term tests of whether management can articulate that shift clearly enough for the gap to close.

What would change our mind: a MolDX denial on either pending RaDaR ST indication, a sustained slowdown in NGS volume growth below 20% in Q3, or any sign that community oncologist adoption is stalling rather than accelerating. Any one of those would tell us the margin expansion has already captured most of what is available and the rest is further out than we think.

Not financial advice.

References

1. NeoGenomics Inc. Form 8-K, Exhibit 99.1, Q2 2026 Earnings Release. US Securities and Exchange Commission EDGAR. Published July 28, 2026. Accessed September 7, 2026. https://www.sec.gov/Archives/edgar/data/0001077183/000107718326000058/a99-106302026earningsrelea.htm
2. NeoGenomics Inc. Form 10-Q for the quarterly period ended June 30, 2026. US Securities and Exchange Commission EDGAR. Published July 28, 2026. Accessed September 7, 2026. https://www.sec.gov/Archives/edgar/data/0001077183/000107718326000059/neo-20260630.htm
3. NeoGenomics Inc. Form 8-K, DOJ and OIG HHS Settlement. US Securities and Exchange Commission EDGAR. Published July 20, 2026. Accessed September 7, 2026. https://www.sec.gov/Archives/edgar/data/0001077183/000107718326000049/neo-20260720.htm
4. First Light Asset Management. Schedule 13G/A for NeoGenomics Inc. US Securities and Exchange Commission EDGAR. Filed April 30, 2026. Accessed September 7, 2026. https://www.sec.gov/Archives/edgar/data/0001077183/000199937126010208/primary_doc.xml
5. Greenhouse Funds. Schedule 13G/A for NeoGenomics Inc. US Securities and Exchange Commission EDGAR. Filed March 31, 2026. Accessed September 7, 2026. https://www.sec.gov/Archives/edgar/data/0001077183/000091957426003445/primary_doc.xml
6. First Trust Portfolios. Schedule 13G for NeoGenomics Inc. US Securities and Exchange Commission EDGAR. Filed June 30, 2026. Accessed September 7, 2026. https://www.sec.gov/Archives/edgar/data/0001077183/000144554626005565/primary_doc.xml
7. NeoGenomics Inc. Second Quarter 2026 Results Press Release. NeoGenomics Investor Relations. Published July 28, 2026. Accessed September 7, 2026. https://ir.neogenomics.com/news-events/press-releases/detail/336/neogenomics-reports-second-quarter-2026-results
8. NeoGenomics Inc. NeoGenomics Receives Medicare Coverage for RaDaR ST for Immunotherapy Treatment Response Monitoring. NeoGenomics Investor Relations. Published August 26, 2026. Accessed September 7, 2026. https://ir.neogenomics.com/news-events/press-releases/detail/337/neogenomics-receives-medicare-coverage-for-radar-st-for-immunotherapy-treatment-response-monitoring
9. NeoGenomics Inc. NeoGenomics to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference. NeoGenomics Investor Relations. Published September 1, 2026. Accessed September 7, 2026. https://ir.neogenomics.com/news-events/press-releases/detail/338/neogenomics-to-participate-in-the-morgan-stanley-24th-annual-global-healthcare-conference
10. NeoGenomics Q2 2026 slides: NGS growth drives margin expansion. Investing.com. Published July 29, 2026. Accessed September 7, 2026. https://www.investing.com/news/company-news/neogenomics-q2-2026-slides-ngs-growth-drives-margin-expansion-93CH-4818256
11. Earnings call transcript: NeoGenomics tops Q2 2026 estimates and lifts outlook. Investing.com. Published July 29, 2026. Accessed September 7, 2026. https://www.investing.com/news/transcripts/earnings-call-transcript-neogenomics-tops-q2-2026-estimates-and-lifts-outlook-93CH-4818244
12. NeoGenomics’s (NASDAQ:NEO) Q2 CY2026: Beats On Revenue. The Globe and Mail. Published July 29, 2026. Accessed September 7, 2026. https://www.theglobeandmail.com/investing/markets/stocks/NEO/pressreleases/3511185/neogenomicss-nasdaqneo-q2-cy2026-beats-on-revenue/
13. NeoGenomics Q1 Earnings Call Highlights. Yahoo Finance. Published April 28, 2026. Accessed September 7, 2026. https://finance.yahoo.com/healthcare/articles/neogenomics-q1-earnings-call-highlights-224735347.html
14. NeoGenomics Inc (NEO) Q2 2026 Earnings Call Highlights. Yahoo Finance. Published July 29, 2026. Accessed September 7, 2026. https://finance.yahoo.com/healthcare/articles/neogenomics-inc-neo-q2-2026-050223556.html
15. NeoGenomics Gets Medicare Coverage for RaDaR ST. StockTitan. Published August 26, 2026. Accessed September 7, 2026. https://www.stocktitan.net/news/NEO/neo-genomics-receives-medicare-coverage-for-ra-da-r-st-for-72msp0nmbpf2.html
16. NeoGenomics Is Up 8.4% After Q2 Profit Return. Yahoo Finance. Published August 2026. Accessed September 7, 2026. https://finance.yahoo.com/markets/stocks/articles/neogenomics-neo-8-4-q2-001543602.html
17. Does NeoGenomics’ (NEO) New PTEN CDx Move Reveal a Deeper Precision Oncology Play? Simply Wall St. Published July 14, 2026. Accessed September 7, 2026. https://simplywall.st/stocks/us/healthcare/nasdaq-neo/neogenomics/news/does-neogenomics-neo-new-pten-cdx-move-reveal-a-deeper-preci
18. How NeoGenomics’ Q2 Profit Return and Higher 2026 Outlook Attract Investors. Simply Wall St. Published August 2026. Accessed September 7, 2026. https://simplywall.st/stocks/us/healthcare/nasdaq-neo/neogenomics/news/how-neogenomics-q2-profit-return-and-higher-2026-outlook-at
19. NeoGenomics Stock Just Turned Its First Profit, Creating an Optimal Entry Point. Barchart. Published August 2026. Accessed September 7, 2026. https://www.barchart.com/story/news/4222217/neogenomics-stock-just-turned-its-first-profit-creating-an-optimal-entry-point
20. NeoGenomics (NEO) Forecast and Analyst Price Targets. StockAnalysis. Accessed September 7, 2026. https://stockanalysis.com/stocks/neo/forecast/
21. NEO Stock Forecast 2026 to 2027. TickerNerd. Accessed August 26, 2026. https://tickernerd.com/stock/neo-forecast/
22. NeoGenomics Inc (NEO) Quote. Morningstar. Accessed September 3, 2026. https://www.morningstar.com/stocks/xnas/neo/quote
23. NEO Stock Quote. CNBC. Accessed September 7, 2026. https://www.cnbc.com/quotes/NEO
24. NEO Stock Price and Chart. TradingView. Accessed September 7, 2026. https://www.tradingview.com/symbols/NASDAQ-NEO/
25. NeoGenomics Inc Investor Relations Summary. Quartr. Published June 4, 2026. Accessed September 7, 2026. https://quartr.com/companies/neogenomics-inc_11926
26. NEO Stock Forecast and Price Target. Public.com. Accessed September 7, 2026. https://public.com/stocks/neo/forecast-price-target